Many thanks to all of you who responded.  Glad to be back on board at
least on RESADM.  Still having trouble with Techno-L that  I put same
message on.  For those of you who asked, yes there should be periods
in address:  it's xxxxxx@osp.emory.edu.  Can't understand what
happended to them unless I forgot to insert.  Apologies.

Now to the reply about clinical trials, which I think I put on at
least three times last week when I wasn't getting through.  If the
following did get through, then disregard the following.

Some years ago, Emory did a survey to learn that it wasn't
competitive with its peer institutions in rate it was charging
pharmaceutical companies for clinical trials.  We dropped the rate
from 30% TDC to 20% TDC.  If anything, we must be too competitive as
we have been getting in at least l0 clinical trial agreements per
week to negotiate.

During the past year, we (like Rochester) has questioned whether we
are giving the government a fair rate since we charge PHS our
federally negotiated rate for these; 20% to privates.

I spoke with Ardis Savory about this as I believe S.C. was also
looking into it.  Ardis told me about a study that Duke was doing:
i.e., was attempting to determine if charging the feds the negotiated
rate based on MTDC wouldn't come out to be about the same by charging
privates a lower rate based on TDC.

I have not heard the outcome of the study and should get in touch
with Duke to hear if they did indeed conduct the study and if so what
were the results.  I heard that if the study showed equity that Duke
was condidering going into feds for other rate that would include
privately sponsored clinical trials.  Again this is all hear-say.  I
should have looked into it further.  Maybe at COGR.

In the meantime, our lowest rate is 20% but of course, we'll take
more if we can get it.

Thanks again for responding to me.  Sure hope this gets through.

Ann R. Stevens,Ph.D.
Phone 404-727-2503
Fax 404-727-2509
xxxxxx@OSPEMORYEDU
Emory University